The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1
The Journal of Dermatology · 2024-08 · 51 (8) · 1050-1059
DOI: 10.1111/1346-8138.17276 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, online erschienen am 24.06.2024. Verfasst von Brieana Dance und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Genetics, Northern Sydney Local Health District, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Quality of Life, Neurofibromatosis 1, Anxiety, Pruritus. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NSW Office of Health and Medical Research, Australia, The Children's Tumour Foundation, Australia.
Abstract (Originalsprache)
The skin manifestations of neurofibromatosis 1 significantly reduce health‐related quality‐of‐life. However, data on the utility of existing surveys in capturing neurofibromatosis 1 skin treatment outcomes are lacking. This quantitative study examined the relationship between clinician‐rated severity and visibility and patient‐rated itch and quality‐of‐life (QoL) to (1) establish baseline levels of skin‐ and condition‐specific‐related QoL, itch, depression and anxiety; (2) identify patient concerns to inform the development and evaluation of skin interventions; and (3) compare the sensitivity of different QoL measures. Validated scales included Skindex‐29, Dermatology Life Quality Index (DLQI), Neurofibromatosis 1‐adult quality‐of‐life (NF1‐AdQOL) questionnaire, and the Hospital Anxiety and Depression Scale (HADS). We recruited 100 participants (response rate: 95%). Of these, 42% reported itch and 23% had probable clinical anxiety. Our cohort had higher levels of anxiety and total HADS scores compared to a control population. Using multivariate regression analysis, increasing visibility significantly predicted poorer QoL using the Skindex‐29, NF1‐AdQOL, and DLQI ( p < 0.05); and itch significantly predicted worse QoL in Skindex‐29 and NF1‐AdQOL ( p < 0.05). The highest mean scoring questions in Skindex‐29 and NF1‐AdQOL concerned worry about worsening skin disease and embarrassment. The highest mean scoring questions in DLQI were regarding itch, pain, and embarrassment. Items asking specifically about cutaneous neurofibromas (cNF) scored higher than comparable skin‐specific questions ( t ‐test p value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Genetics, Northern Sydney Local Health District, Sydney, New South Wales, Australia.
- Northern Clinical School, Faculty of Health and Medicine, University of Sydney, Sydney, New South Wales, Australia.
- Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
- Department of Dermatology, Northern Sydney Local Health District, Sydney, New South Wales, Australia.
ORCID-Profile: Brieana Dance, Jane Fleming, Sue-Faye Siow, Yemima Berman
Förderung
- NSW Office of Health and Medical Research, Australia
- The Children's Tumour Foundation, Australia
Zitieren
APA
Dance, B., Dardare, A., Fleming, J., Siow, S. F., Schlub, T. E., Crawford, H., Saunderson, R. B., Wong, C., & Berman, Y. (2024). The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1. The Journal of Dermatology, 51(8), 1050-1059. https://doi.org/10.1111/1346-8138.17276
Vancouver
Dance B, Dardare A, Fleming J, Siow SF, Schlub TE, Crawford H, et al. The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1. The Journal of Dermatology. 2024;51(8):1050-1059. doi:10.1111/1346-8138.17276
BibTeX
@article{Dance2024,
author = {Dance, Brieana and Dardare, Alice and Fleming, Jane and Siow, Sue-Faye and Schlub, Timothy E and Crawford, Hilda and Saunderson, Rebecca B and Wong, Claire and Berman, Yemima},
title = {The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1},
journal = {The Journal of Dermatology},
year = {2024},
volume = {51},
number = {8},
pages = {1050--1059},
doi = {10.1111/1346-8138.17276}
}
EUVIMED